Skip to main content
    T

    Taysha Gene Therapies Inc (TSHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.06
    -0.04 (-0.98%)

    Market Cap: $1.34B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Taysha Gene Therapies Inc (TSHA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Taysha Gene Therapies (TSHA) to earn -$0.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.71M. Of 13 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.77, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy323.1%
    Buy1076.9%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 784.9%.

    Fiscal year ending Dec 31, 2026
    -$0.39
    EPS consensus, revenue $2.71M
    Fiscal year ending Dec 31, 2027
    -$0.40
    EPS consensus, revenue $23.98M
    Next report
    Mar 17, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.39-$0.43 to -$0.353$2.71MN/A7
    Dec 31, 2027-$0.40-$0.55 to -$0.314$23.98MN/A5

    Quarterly Estimates

    The EPS consensus rises from -$0.13 for the quarter ending Dec 31, 2026 to -$0.10 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.13-$0.15 to -$0.1214$382500N/A13
    Mar 31, 2027-$0.10-$0.13 to -$0.083$1.60MN/A3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 8 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202603
    Fiscal year ending Dec 31, 202703
    Quarter ending Mar 31, 202702

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.47.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.39-$0.47-$0.47-$0.47-$0.47N/A
    Fiscal year ending Dec 31, 2027-$0.40-$0.46-$0.46-$0.46-$0.48N/A
    Quarter ending Mar 31, 2027-$0.10-$0.12-$0.12-$0.12-$0.13N/A

    Frequently Asked Questions About TSHA

    What is the TSHA stock forecast?

    Consensus analyst estimates put Taysha Gene Therapies's EPS at -$0.39 for the fiscal year ending Dec 31, 2026, on revenue of $2.71M. The consensus rating from 13 analysts is Buy.

    How do analysts rate TSHA stock?

    Of 13 analysts covering Taysha Gene Therapies, 3 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TSHA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.39, with estimates from -$0.43 to -$0.35 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.40, with estimates from -$0.55 to -$0.31 from 4 analysts.

    What revenue do analysts expect from Taysha Gene Therapies next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.71M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $23.98M.

    How many analysts cover TSHA?

    13 analysts rate Taysha Gene Therapies stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.